Imagine a baby born in 2045. It may not only live to be 150 years old—but also walk, think, and work actively at that age. This is not a scene from *Blade Runner*. It is a projection based on clinical data, billion-dollar investments, and experiments currently running in Harvard, Stanford, and Altos Labs.
Altos Labs—a company funded by Jeff Bezos with $3 billion—does not pursue 'immortality.' It pursues *cell reprogramming*: reversing the biological clock of adult cells so they function like embryonic cells. Early results in mice show improved brain, liver, and muscle function—without tumors or genetic instability. At Calico, scientists are testing drugs targeting *mTOR* and *sirtuins*, two metabolic pathways that act as 'speed governors' of aging. Rapamycin, originally an organ transplant drug, is now being tested in phase II trials to slow neural degeneration in humans.
From diagnosis to prediction before symptoms appear
Medicine no longer waits for disease to come. Liquid biopsies—analyzing dead cells in blood—can detect cancer mutations five to seven years before a tumor can be seen on an MRI. Full-body AI scanning platforms like PathAI or Paige detect pre-cancerous lesions with accuracy exceeding that of expert radiologists. In 2023, CRISPR treatment for sickle cell anemia was not only successful—it was approved by the UK MHRA and US FDA. The next step? Editing genes *APOE4*, *TREM2*, or *PCSK9* early in life—not to 'fix,' but to *prevent* Alzheimer's or heart attacks entirely.
But no technology comes without shadows. Germline editing—which alters DNA in sperm or eggs—can be inherited. If allowed without limits, it opens the door to genetic engineering: not just disease-free, but 'taller,' 'more stress-resistant,' 'faster learners.' And who will have access to it? A single CRISPR treatment currently costs $2.2 million. That price is not about cost—it is a *social barrier*.
Epigenetics: Not the code itself that changes, but the way it is read
Our genes do not change since birth. What changes are *epigenetic markers*: molecules that attach to DNA and turn certain genes on or off. As we age, these markers accumulate—and cells start to 'forget' how to function. Scientists can now read the 'epigenetic clock' with ±3.5 year accuracy from a blood sample. More intriguingly, some markers can be reversed. Intermittent fasting, intense endurance training, and drugs like metformin have shown real effects in 'reprogramming' the epigenetic profile of adult humans.
This combination—pharmaceuticals + lifestyle—is not about living longer for the sake of it. It is about *healthspan*: extending the time of life *with full function*, not just *lifespan* with decades dependent on assistive devices.
Retirement, population, and the rights of immortality
If the average active senior lives to 120, an age-based pension system at 60 would collapse within one generation. The concept of a 'lifetime career' is already outdated—but education systems, student loans, and retraining schemes have not caught up. In Japan, 29% of the population is over 65. Imagine if that number rose to 45%—and half of them were between 90 and 120.
Global population may not explode—birth rates continue to fall in 95 countries—but pressure on water, arable land, and energy will increase sharply. Economist Tyler Cowen is not wrong: longer life is not a 'free gift.' It is an ecological and institutional commitment that must be rebuilt from the ground up.
And the most bitter question remains unanswered: should longevity be a human right—as basic as clean water or elementary education? Or will it become an exclusive luxury, deepening the gap between those who are 'recreated' and those who are 'left to age'?
We have reached the crossroads—not the starting line
Global investments in aging biotechnology exceed $30 billion in 2024. The first clinical trials for stem cell-based anti-aging therapies will begin this year in Singapore and Zurich. Science no longer asks *can or cannot*. It asks: *want or not?* And the answer is not just for scientists—it is for every teacher, fisherman, student, and grandmother who still washes their own clothes today. The question is no longer whether we *can* live 150 years. But whether we *want* to live in a world that is willing to bear the burden—and celebrate the blessings—that come with it.